Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study

Mauro G. Trovò, Umberto Tirelli, Antonino De Paoli, Giovanni Franchin, Mario Roncadin, M. Donatella Magri, Enzo Galligioni, Andrea Veronesi, Salvatore Tumolo, Antonino Carbone, Eligio Grigoletto

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty-four consecutive patients with inoperable epidermoid bronchogenic carcinoma (limited disease) were treated with radiotherapy to the primary and nodal areas and combination chemotherapy with cyclophosphamide, adriamycin, methotrexate and procarbazine. The overall response rate (CR + PR) to combined treatment was 62%. The median survival time was 12.7 months. The toxicity was acceptable and no treatment-related death occurred.

Original languageEnglish
Pages (from-to)1051-1054
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume8
Issue number6
DOIs
Publication statusPublished - 1982

Keywords

  • Combined radio- and chemotherapy
  • Epidermoid bronchogenic carcinoma
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study'. Together they form a unique fingerprint.

Cite this